Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. 1992

R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
Department of Pharmacy, University of Tennessee College of Medicine, Memphis.

The pharmacokinetics of oral nifedipine were studied in 15 women with pregnancy-induced hypertension in the third trimester of pregnancy to determine if the drug's disposition was different from that in nonpregnant patients. Peak serum concentrations of 38.6 +/- 18 ng/ml occurred at approximately 40 minutes after ingestion of nifedipine 10 mg. The terminal elimination half-life (mean 1.3 +/- 0.5 hrs) was shorter than that reported for normotensive volunteers and nonpregnant hypertensives after oral dosing. Mean +/- SD apparent elimination clearance of 2.0 +/- 0.8 L/hr/kg was more rapid than that in healthy volunteers (mean 0.49 +/- 0.09 L/hr/kg). Random serum concentrations were progressively higher in patients receiving larger daily doses. Nifedipine was detected in samples of fetal cord blood and amniotic fluid at concentrations approximately 93% and 53% those of simultaneous maternal vein samples, respectively. The findings indicate that nifedipine may achieve greater antihypertensive efficacy in pregnant women if administered at shorter intervals.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011249 Pregnancy Complications, Cardiovascular The co-occurrence of pregnancy and a cardiovascular disease. The disease may precede or follow FERTILIZATION and it may or may not have a deleterious effect on the pregnant woman or FETUS. Cardiovascular Pregnancy Complications,Complications, Cardiovascular Pregnancy,Pregnancy, Cardiovascular Complications,Cardiovascular Pregnancy Complication,Complication, Cardiovascular Pregnancy,Pregnancies, Cardiovascular Complications,Pregnancy Complication, Cardiovascular
D011263 Pregnancy Trimester, Third The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation. Pregnancy, Third Trimester,Trimester, Third,Last Trimester,Last Trimesters,Pregnancies, Third Trimester,Pregnancy Trimesters, Third,Third Pregnancy Trimester,Third Pregnancy Trimesters,Third Trimester,Third Trimester Pregnancies,Third Trimester Pregnancy,Third Trimesters,Trimester, Last,Trimesters, Last,Trimesters, Third
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
February 1990, American journal of obstetrics and gynecology,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
June 1994, The Ceylon medical journal,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
February 1993, Journal of clinical pharmacology,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
November 1996, Zhonghua fu chan ke za zhi,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
December 2006, The Nigerian postgraduate medical journal,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
January 2015, International journal of cardiology,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
April 1991, British journal of clinical pharmacology,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
April 1993, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
November 2015, Seminars in perinatology,
R R Prevost, and S A Akl, and W D Whybrew, and B M Sibai
November 2017, Endocrine connections,
Copied contents to your clipboard!